Kokaliaris, Christos
Evans, Rachel
Hawkins, Neil
Mahajan, Anadi
Scott, David Alexander
Sutherland, C. Simone
Nam, Julian
Sajeev, Gautam
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd
Article History
Received: 18 December 2023
Accepted: 13 March 2024
First Online: 5 May 2024
Declarations
:
: The SLR and data extraction were conducted by Bridge Medical Consulting Ltd., London, UK and funded by F. Hoffmann-La Roche Ltd., Basel, Switzerland. ITC analyses were designed by Visible Analytics, UK, funded by F. Hoffmann-La Roche Ltd. Christos Kokaliaris and Julian Nam are employees of F. Hoffmann-La Roche Ltd. Julian Nam owns stocks in Roche. Rachel Evans is a former employee of Visible Analytics Ltd., which designed the analysis and received consultancy fees and expenses from F. Hoffmann-La Roche Ltd. Neil Hawkins and David Alexander Scott are partners/employees of Visible Analytics Ltd., which designed the analysis and received consultancy fees and expenses from F. Hoffmann-La Roche Ltd. Anadi Mahajan is an employee of Bridge Medical Consulting Ltd., which conducted this SLR and received consultancy fees and expenses from F. Hoffmann-La Roche Ltd. C Simone Sutherland was employed by F. Hoffmann-La Roche Ltd and owns stocks in Roche. Gautam Sajeev is an employee of Analysis Group, Inc. which received consulting fees from Genentech Inc. (a member of the Roche group) for this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: This study did not require ethical approval as data were obtained from published studies. FIREFISH and ENDEAR received institutional review board approval and were conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained for patient participation in these studies. The data published in this article is owned by F. Hoffmann-La Roche. Roche has the necessary permissions to share with readers upon reasonable request.